COVID Vaccine Eligibility: Who’s Eligible & How?
- Recent changes to COVID-19 vaccine labeling by the Food and Drug Administration (FDA) have created uncertainty regarding access for individuals who do not meet the newly defined high-risk...
- The FDA transitioned the vaccines to a traditional market model, similar to the annual flu shot, in May 2024.
- Pharmacists face significant legal and professional hurdles when considering administering vaccines off-label.
COVID-19 Vaccine Access and Off-Label Use: A Current Overview (Updated September 6, 2024)
Table of Contents
Current Situation: FDA and CDC Guidance
Recent changes to COVID-19 vaccine labeling by the Food and Drug Administration (FDA) have created uncertainty regarding access for individuals who do not meet the newly defined high-risk criteria. Previously, the FDA allowed broader access, but the updated guidelines have narrowed eligibility, prompting questions about off-label use and the role of pharmacists and physicians.
The FDA transitioned the vaccines to a traditional market model, similar to the annual flu shot, in May 2024. This shift means the vaccines are now regulated differently, and access is primarily intended for those considered at high risk of severe COVID-19 outcomes.The FDA published a list of qualifying high-risk conditions in May, but did not officially adopt it when finalizing the vaccine label changes last month, leading to ambiguity.
Pharmacist Limitations and “Corresponding Duty”
Pharmacists face significant legal and professional hurdles when considering administering vaccines off-label. “It’s very gray on how a pharmacist may proceed in that scenario,” explained Sarah Groves, a pharmacy law expert, in an interview with Ars Technica (“FDA’s COVID vaccine shift leaves pharmacists in a tricky spot,” Ars Technica, August 29, 2024). Going off-label could expose pharmacists to liability concerns.
Even with a prescription for off-label use, pharmacists are bound by “corresponding responsibility.” Groves clarified this means a pharmacist must independently verify that the vaccine is appropriate for the specific patient, considering their medical history and current health status. This includes ensuring the correct medication, dosage, and timing. Therefore, administering a vaccine outside of the FDA-authorized uses remains a complex legal and ethical issue for pharmacists.
Physician Discretion and Off-Label Use
unlike pharmacists, physicians retain the ability to administer vaccines off-label.They can base their decisions on guidance from medical organizations like the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG), or on their professional judgment regarding a patient’s individual needs. Doctors can do so without facing the same heightened professional liability as pharmacists, as off-label prescribing is a common medical practice.
However, accessing a vaccine through a physician may require scheduling an appointment and convincing the doctor it’s the best course of action, which is less convenient then visiting a pharmacy. Moreover, manny doctors’ offices may not currently stock COVID-19 vaccines, as pharmacies have been the primary distribution point during the pandemic.
The Status of Pregnancy as a high-Risk Condition
The inclusion of pregnancy as a high-risk condition is currently unclear. While pregnancy was initially included on the FDA’s list of qualifying conditions published in May 2024, it was not officially adopted when the vaccine labels were updated. Some experts suggest that, in the absence of explicit FDA guidance, pregnancy should default to being considered a high-risk condition based on the Centers for Disease Control and Prevention’s (CDC) existing list of high-risk conditions. However, this interpretation remains subject to debate and clarification.
The CDC’s list includes conditions such as cancer, chronic kidney disease, chronic lung diseases, diabetes, heart conditions, immunocompromised state, obesity, and sickle cell disease. The ambiguity surrounding pregnancy highlights the broader challenges in interpreting the new FDA guidelines and ensuring equitable access to vaccination.